Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts

AstraZeneca1,200 enrolled

Overview

This study is an observational study to see whether anxiety level can be correlated with PSA level under the current practice in the patients of prostate cancer taking hormonal therapy. For assessment of anxiety level BAI(Beck Anxiety Inventory) will be used. The target population for this study is the patients of prostate cancer diagnosed previously and who are taking hormonal therapy with regular follow-up and PSA test. The follow-up duration will be total 6 months with interim visit at 3 month and final visit at 6 month.

Study Type

OBSERVATIONAL

Enrollment

1,200

Conditions

Prostate Cancer

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Provision of written informed consent 2. Patients who take PSA test regularly 3. Observation suitable patients for PSA change according to hormonal treatment at least for 6months 4. Locally advanced or advanced prostate cancer patients who is suitable for hormonal therapy 5. Prostate Cancer Patients who has been taking one treatment among 3 hormonal therapies in below: * Bicalutamide Monotherapy : Bicalutamide 150mg/day * Goserelin 3.6mg/10.8mg * MAB(Maximal Androgen Blockade) :Bicalutamide 50mg + Goserelin 3.6/10.8mg Exclusion Criteria: 1. Prohibition use under permitted indication 2. Previous inclusion in the present study 3. Participation in a clinical study during the last 30 days

Locations (3)

Research Site

Kyunggi, Anyang-si Dongan-gu, South Korea

Research Site

Seoul, Jongro-gu, South Korea

Research Site

Seoul, Songpa-gu, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.